Linker Information
General Information of This Linker (ID: LIN0SXVHL)
| Name |
β-glucuronide linker
|
|||||
|---|---|---|---|---|---|---|
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
|
|
||||||
| Isosmiles |
OCC1=CC=C(C(C(NCCOCCOCCO/N=C(CC/C(C)=C/CC/C(C)=C/CS)\C)=O)=C1)O[C@@H]2O[C@@H]([C@@H]([C@@H]([C@@H]2O)O)O)C(O)=O
|
|||||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
caxmotabart entudotin [Phase 3]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
66.70
42.90 % |
|||
| Patients Enrolled |
Patients with HER2-expresssing advanced solid tumors who had failed prior standard of care therapies.
|
||||
| Administration Dosage |
FS-1502 was given IV once in 21-day or 28-day cycle at doses of 0.10-3.50 mg/kg.
|
||||
References